Establishment and validation of prognostic nomograms integrating histopathological features in patients with invasive endocervical adenocarcinoma

LI-LI Liu (liulil@sysucc.org.cn)  
Sun Yat-sen University Cancer Center  
https://orcid.org/0000-0002-4347-2038

Shu-Lin Chen  
Sun Yat-sen University Cancer Center

Xia Yang  
Sun Yat-sen University Cancer Center

Yue Li  
Sun Yat-sen University Cancer Center

Shi-Wen Zhang  
Sun Yat-sen University Cancer Center

Yan-Lin Wen  
Sun Yat-sen University Cancer Center

Rong-Zhen Luo  
Sun Yat-sen University Cancer Center

Primary research

Keywords: Histological features, Invasive endocervical adenocarcinoma, LASSO–Cox regression model, Prognosis

DOI: https://doi.org/10.21203/rs.3.rs-123003/v1

License: ☑️ This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

Background

To develop and verify pathological models using pathological features basing on hematoxylin and eosin (H&E) images to predict postoperative survival in patients with invasive endocervical adenocarcinoma (ECA).

Method:

There were 289 patients with ECA classified into training and validation cohorts. A histological signature was produced in 191 patients and verified in the validation group. Histological models combining the histological features were built. They showed increased value compared to the conventional model in terms of individualized prognosis estimation.

Results

Our model included five selected histological characteristics and was significantly related to overall survival (OS). In the training cohort, it had AUC values of 0.862 and 0.955, respectively, for predicting 3- and 5-year survival; in the validation cohort, the equivalent values were 0.891 and 0.801. In the training cohort, it showed better OS evaluation (C-index: 0.832; 95% confidence interval [CI] = 0.751–0.913) than both the FIGO staging system (C-index: 0.648; 95% CI = 0.542–0.753) and treatment (C-index: 0.687; 95% CI = 0.605–0.769), with advanced efficiency for classifying survival outcomes. In both cohorts, a risk stratification system was built that could precisely stratify patients with stage I and II ECA into high-risk and low-risk subpopulations with significantly different prognoses.

Conclusion

Our nomogram with five histological signatures had better accuracy in the prediction of OS in patients with ECA. This may contribute to the development of precision medicine in such patients.

Introduction

Endocervical adenocarcinoma (ECA) comprises approximately 25% of cervical cancers. It is much more heterogeneous than other types of cervical tumors, with around 15% of cases being unrelated to human papillomavirus (HPV) infection. ECA has a higher prevalence than squamous cell carcinoma because it is difficult to detect glandular lesions using cytological screening[1]. According to the International Endocervical Adenocarcinoma Criteria and Classification (IECC), ECA is categorized into HPV-associated (HPVA) and non-HPV-associated (NHPVA) types. Although most cases of ECA are associated with HPV infection, NHPVA is challenging to diagnose and tends to be aggressive[2–6]. Furthermore, International
Federation of Gynecology and Obstetrics (FIGO) stage is the most critical parameter for determining treatment and prognosis, but significant heterogeneities in clinical prognosis occur among patients with ECA who show similar FIGO stage. Therefore, to improve prognosis in patients with ECAs, researchers must ascertain the substantial prognostic determinants.

ECAs are classified based on descriptive morphological characteristics, particularly cytoplasmic features[7]. However, ECAs cannot easily be categorized using the 2014 World Health Organization classification because they are defined based on empirical observation, rather than on clinical or biological features[7]. In our own studies, we have used the IECC classification for histological typing. Previous studies have identified several pathological variables with prognostic value in ECA, namely tumor size, depth of invasion (DOI), lymphovascular invasion (LVI), and lymph node metastasis (LNM)[8, 9]. Therefore, combined analysis of histological features is the most promising approach to improving clinical management. Previous studies have shown that this histological model is correlated with outcomes in patients with ECA. However, to our knowledge, no strategy has been developed that uses histological signatures to predict outcome.

In the present study, we generated and verified a histological feature-based histological model to predict outcomes. This histological model may accurately stratify patients with ECA into high- and low-risk groups.

Materials And Methods

Patients and samples

In the present retrospective study, we enrolled 289 patients with histologically confirmed ECA who had been treated at the Sun Yat-sen University Cancer Center between January 2010 and December 2014. Patients were enrolled when (1) they had been diagnosed with primary ECA, and (2) they had complete clinical data available. The exclusion criteria were as follows: (1) systemic metastasis at diagnosis, (2) co-existing malignancies, (3) history of anti-cancer therapy. Patients were classified into either the training group (n = 200) or the validation group (n = 89). The last follow-up was conducted in June 2020. The Hospital Ethics Committee at the Sun Yat-sen University Cancer Center, China approved this study. The critical raw data associated with this article have been uploaded onto the Research Data Deposit public platform (www.researchdata.org.cn), with the following RDD approval number: RDD2020001505.

Histologic features

All slides were evaluated by histologists who had no knowledge of the corresponding patient information. In accordance with the new pathogenetic classification of the IECC, ECA was classified into HPVA and NHPVA histological types[10]. In all samples, the invasive patterns of the tumors were categorized as A, B, or C[11–14]. The following features were evaluated: nuclear grade, tumor cell necrotic debris, mitosis/10 high-power fields (HPF), tumor giant cells/10 HPF, LVI, tumoral tumor-infiltrating lymphocytes (TILs), stromal TILs, differentiation, DOI, stromal invasion, nerve invasion, endometriosis invasion, LNM,
extranodal involvement, and parametrium invasion. Tumor cell necrotic debris was classified as focal, moderate, or extensive. Nuclear grade was classified as previously reported[15]. Mitosis was calculated in 10 high power fields (HPF), as were tumor giant cells, which were categorized as either multi-nucleated tumor giant cells or single giant nuclear cells, with a nucleus 3–4 times bigger than the surrounding tumor nuclei. These cells are usually identified using low power (4×) or intermediate power (10×) microscopy. Following a standardized method, TILs were evaluated on hematoxylin and eosin (H&E)-stained slides to provide a percentage score for stromal and intratumoral compartments, as described previously[16]. The H&E images of these features are shown in Supplementary Figs. 1 and 2.

**Construction and validation of the nomogram**

In the construction of the nomogram, we combined the following clinical variables and histological factors as prognostic characteristics: age, menopause, oral contraceptive use, chief complaint, histological type, FIGO stage, tumor size, differentiation, growth pattern, nuclear grade, tumor cells necrotic debris, mitosis/10HPF, tumor giant cells/10HPF, tumoral TILs, stromal TILs, LVI, DOI, stromal invasion, nerve invasion, endometrial invasion, LNM, extranodal involvement, parametrium invasion, and treatment. We used the least absolute shrinkage and selection operator (LASSO) regression with 10-fold cross-validation to choose the most useful predictive markers and create nomograms of overall survival (OS) from the training cohort.

**Statistical Analysis**

We used IBM SPSS Statistical software version 19.0 (IBM Corp., Chicago, IL, USA) and R version 3.4.0 (http://www.R-project.org/) for statistical analyses. Survival curves were conducted using the Kaplan–Meier approach.

**Results**

**Patient characteristics and survival**

The patients’ clinicopathological features are listed in Table 1. No differences were observed in terms of age, therapeutic data (chemotherapy with or without radiotherapy), oral contraceptive usage, chief complaint, histological type, tumor size, differentiation, growth pattern, nuclear grade, tumor cells necrotic debris, mitosis/10HPF, giant cells/10HPF, tumoral TILs, stromal TILs, LVI, DOI, stromal invasion, nerve invasion, LNM, parametrium invasion, or FIGO stage. In the training and validation groups, the median follow-up periods were 59.4 months (range: 3.6–124.5 months) and 67.4 months (range: 1.5–122.7 months). Moreover, the 1-, 3-, and 5-year OS rates were 97.9%, 92.6%, 89.0%, respectively, in the training group and 96.9%, 91.8%, 89.8%, respectively in the validation groups.
| Characteristic          | All patients | Training cohort | Validation cohort |
|------------------------|--------------|-----------------|-------------------|
|                        | No. (%)      | No. (%)         | No. (%)           |
| Total                  | 289          | 191             | 98                |
| Age (y)*               | 45 (40–52)   | 45 (40–51)      | 45 (40.8–52)      |
| Menopause              |              |                 |                   |
| No                     | 222 (76.8%)  | 148 (77.5%)     | 74 (75.5%)        |
| Yes                    | 67 (23.2%)   | 43 (22.5%)      | 24 (24.5%)        |
| OCP usage              |              |                 |                   |
| No                     | 282 (97.6%)  | 184 (96.3%)     | 98 (100%)         |
| Yes                    | 7 (2.4%)     | 7 (3.7%)        | 0 (0.0%)          |
| Main clinical finding  |              |                 |                   |
| Vaginal bleeding       | 220 (76.1%)  | 136 (71.2%)     | 84 (85.7%)        |
| Mucoid discharge       | 15 (5.2%)    | 14 (7.3%)       | 1 (1.0%)          |
| Other                  | 54 (18.7%)   | 41 (21.5%)      | 13 (13.3%)        |
| Histological type      |              |                 |                   |
| HPVA                   | 27 (9.3%)    | 20 (10.5%)      | 7 (7.1%)          |
| NHPVA                  | 262 (90.7%)  | 171 (89.5%)     | 91 (92.9%)        |
| FIGO stage             |              |                 |                   |
| I                      | 205 (70.9%)  | 131 (68.6%)     | 74 (75.5%)        |
| II                     | 72 (24.9%)   | 51 (26.7%)      | 21 (21.4%)        |
| III                    | 9 (3.1%)     | 6 (3.1%)        | 3 (3.1%)          |
| IV                     | 3 (1.6%)     | 3 (1.6%)        | 0 (0.0%)          |
| Tumor size (cm)*       | 3 (2–4)      | 3 (2–4)         | 2.5 (2.0-3.5)     |
| Differentiation        |              |                 |                   |
| Good                   | 12 (4.2%)    | 9 (4.7%)        | 3 (3.1%)          |
| Moderate               | 156 (54.0%)  | 107 (56.0%)     | 49 (50.0%)        |
| Poor                   | 121 (41.8%)  | 75 (39.3%)      | 46 (46.9%)        |

*Data in parentheses are interquartile ranges.
| Characteristic                  | All patients | Training cohort | Validation cohort |
|--------------------------------|--------------|----------------|-------------------|
|                                | No. (%)      | No. (%)        | No. (%)           |
| Growth pattern                 |              |                |                   |
| A                              | 26 (9.0%)    | 17 (8.9%)      | 9 (9.2%)          |
| B                              | 34 (11.8%)   | 20 (14.3%)     | 14 (14.3%)        |
| C                              | 229 (79.2%)  | 154 (80.6%)    | 75 (76.5%)        |
| Nuclear grade                  |              |                |                   |
| 1                              | 38 (13.1%)   | 29 (15.2%)     | 9 (9.2%)          |
| 2                              | 153 (52.9%)  | 96 (50.3%)     | 57 (58.2%)        |
| 3                              | 98 (33.9%)   | 66 (34.6%)     | 32 (32.7%)        |
| Tumor cell necrotic debris     |              |                |                   |
| Focal                          | 185 (64.0%)  | 121 (63.4%)    | 64 (65.3%)        |
| Moderate                       | 55 (19.0%)   | 43 (22.5%)     | 12 (12.2%)        |
| Extensive                      | 49 (17.0%)   | 27 (14.1%)     | 22 (22.4%)        |
| Mitosis/10HPF*                 | 31 (16–50)   | 31 (15–50)     | 30 (17.8–48.5)    |
| Number of tumor giant cells/10HPF* | 0 (0–0) | 0 (0–0) | 0 (0–0) |
| LVI                            |              |                |                   |
| None                           | 200 (69.2%)  | 127 (66.5%)    | 73 (74.5%)        |
| Focal                          | 56 (19.4%)   | 42 (22.0%)     | 14 (14.3%)        |
| Moderate                       | 18 (6.2%)    | 10 (5.2%)      | 8 (8.2%)          |
| Extensive                      | 15 (5.2%)    | 12 (6.3%)      | 3 (3.1%)          |
| Tumoral TILs (%) *             | 1 (1–1)      | 1 (1–1)        | 1 (1–1)           |
| Stromal TILs (%) *             | 20 (10–50)   | 20 (10–50)     | 20 (10–50)        |
| Depth of invasion (mm)*        | 12 (8–16)    | 12 (8–17)      | 12.5 (7–16)       |
| Cervical stromal invasion      |              |                |                   |
| Inner 1/3                      | 77 (26.6%)   | 49 (25.7%)     | 28 (28.6%)        |
| Middle 1/3                     | 91 (31.5%)   | 58 (30.4%)     | 33 (33.7%)        |
| Outer 1/3                      | 121 (41.9%)  | 84 (44.0%)     | 37 (37.8%)        |

*Data in parentheses are interquartile ranges.
| Characteristic                  | All patients | Training cohort | Validation cohort |
|--------------------------------|--------------|-----------------|-------------------|
|                               | No. (%)      | No. (%)         | No. (%)           |
| Nerve invasion                 |              |                 |                   |
| No                             | 262 (90.7%)  | 173 (90.6%)     | 83 (90.8%)        |
| Yes                            | 27 (9.3%)    | 18 (9.4%)       | 9 (9.2%)          |
| Endometriosis invasion         |              |                 |                   |
| No                             | 232 (80.3%)  | 145 (75.9%)     | 87 (88.8%)        |
| Yes                            | 57 (19.7%)   | 46 (24.1%)      | 11 (11.2%)        |
| Lymph node metastasis          |              |                 |                   |
| No                             | 225 (77.9%)  | 145 (75.9%)     | 80 (81.6%)        |
| Yes                            | 64 (22.1%)   | 46 (24.1%)      | 18 (18.4%)        |
| Extra nodal involvement        |              |                 |                   |
| No                             | 256 (88.6%)  | 167 (87.4%)     | 89 (90.8%)        |
| Yes                            | 33 (11.4%)   | 24 (12.6%)      | 9 (9.2%)          |
| Parametrium invasion           |              |                 |                   |
| No                             | 267 (92.4%)  | 176 (92.1%)     | 91 (92.9%)        |
| Yes                            | 22 (7.6%)    | 15 (7.9%)       | 7 (7.1%)          |
| Treatment                      |              |                 |                   |
| Surgery                        | 109 (37.7%)  | 71 (37.2%)      | 38 (38.8%)        |
| Surgery + radiotherapy         | 61 (21.1%)   | 44 (23.0%)      | 17 (17.3%)        |
| Surgery + chemotherapy         | 38 (13.1%)   | 24 (12.6%)      | 14 (14.3%)        |
| Surgery + radiotherapy/chemotherapy | 81 (28.0%) | 52 (27.2%) | 29 (29.6%) |

*Data in parentheses are interquartile ranges.

**Development and validation of the histopathological nomogram**

A multiple-feature-based histological signature was built to prognose survival in the training group. After applying the LASSO logistic algorithm, five of the 22 clinical and histopathological features were finally used to develop our model (Fig. 1A and 1B). The following histopathological features had a non-zero coefficient: histological type, DOI, stromal invasion, LVI, and LNM. Histological images of the above five features are presented in Supplementary Fig. 1. Our model was created using the following formula: risk
score = histological type · -0.066 + DOI · 0.002 + stromal invasion · 0.218 + LVI · 0.123 + LNM · 0.534. The contribution of each selected variable to signature construction is shown in Fig. 1C.

These factors were used to develop nomogram models in the training and validation groups. The histological nomograms, FIGO stage, treatment, and OS are presented in Fig. 2A and 2B. We noticed a decent calibration curve, which confirmed good agreement between prediction and observation for 1-, 3-, and 5-year OS in the training and validation cohorts (Fig. 2C–2H).

In the training cohort, the AUCs of our 3- and 5-year models were 0.882 and 0.891, respectively (Fig. 3A and 3C). The nomogram subsequently created was confirmed in the validation group. The AUCs of our models were 0.955 and 0.801 for 3- and 5-year OS, respectively, in the validation group (Fig. 3B and 3D).

**Comparing predictive accuracy between our model and the FIGO staging system**

In the training group, our model showed better discrimination ability (C-index: 0.832; 95% CI = 0.751–0.913) than both the FIGO system (C-index: 0.648; 95% confidence interval [CI] = 0.542–0.753) and treatment (C-index: 0.687; 95% CI = 0.605–0.769; p = 0.001 for both comparisons; Table 2). In the validation group, our model showed better discrimination ability (C-index: 0.822; 95% CI = 0.691–0.952; p = 0.033 and p = 0.071) than the FIGO staging system (C-index: 0.599; 95% CI = 0.437–0.761) and treatment (C-index: 0.693; 95% CI = 0.513–0.872). Decision curve analysis showed that our model had higher overall net benefit (Fig. 3E and 3F).
Table 2

The C-index of our model, Figo stage, Treatment for prediction of OS in training and validation cohort.

| Factors                        | C-index | 95 CI%         | P     |
|--------------------------------|---------|----------------|-------|
| **For training cohort**        |         |                |       |
| Our model                      | 0.832   | 0.751–0.913    |       |
| Figo stage                     | 0.648   | 0.542–0.753    |       |
| Treatment                      | 0.687   | 0.605–0.769    |       |
| Our model vs Figo stage        |         |                | 0.001 |
| Our model vs Treatment         |         |                | 0.001 |
| **For validation cohort**      |         |                |       |
| Our model                      | 0.822   | 0.691–0.952    |       |
| Figo stage                     | 0.599   | 0.437–0.761    |       |
| Treatment                      | 0.693   | 0.513–0.872    |       |
| Our model vs Figo stage        |         |                | 0.033 |
| Our model vs Treatment         |         |                | 0.071 |

Our model includes histological type, lymph vascular invasion, depth of invasion, invasion level of uterine cervix and lymph nodes invasion;

C-index = concordance index; P values are calculated based on normal approximation using function rcorrp.cens in Hmisc package.

Risk stratification of OS

At a cutoff risk-score of -1.62 (Supplementary Fig. 3), patients were categorized into high-risk (> -1.62) and low-risk groups (≤ -1.62). The OS rate in the two groups is listed in Table 3. In the training cohort, the 1-, 3-, and 5-year OS rates were 93.2%, 79.5%, 65.9%, respectively, in the high-risk group, and 99.3%, 96.6%, and 95.9%, respectively in the low-risk group (Table 3). In the validation cohort, the 1-, 3-, and 5-year OS rates were 94.4%, 66.7%, 66.7%, respectively, in the high-risk group, and 97.5%, 97.5%, 95.0%, respectively, in the low-risk group (Table 3). Likewise, significant differences were observed for OS in patients with stage I, II, and whole ECA in the training and validation cohorts. Patients with lower risk scores generally had a better OS (Fig. 4). Each risk subgroup represented a distinct prognosis, and this system accurately separated OS in the two subgroups. Furthermore, our clustering approach revealed C1 and C2 patient groups in both cohorts (Fig. 5A and 5B). In the training and validation cohorts, the correlation coefficient between our model and FIGO stage was similar to that between our model and treatment (Fig. 5C and 5D). There were significantly positive correlations between our model, FIGO stage, and treatment in both cohorts (Table 4).
Table 3. OS rate in high-risk and low-risk groups.

| Parameter | Training cohort (n=191) | Validation cohort (n=98) |
|-----------|-------------------------|--------------------------|
|           | High-risk group | Low-risk group | Total | High-risk group | Low-risk group | Total |
| No. of patients | 44 | 147 | 191 | 18 | 80 | 98 |
| Median (m)* | 36.1(12.0-56.2) | 66.9(52.5-84.5) | 59.4(39.1-79.7) | 26.4(16.1-67.1) | 73.2(56.4-88.0) | 67.4(47.7-85.6) |
| 1-Year OS (%) | 41(93.2%) | 146(99.3%) | 187(97.9%) | 17(94.4%) | 78(97.5%) | 95(96.9%) |
| 3-Year OS (%) | 35(79.5%) | 142(96.6%) | 177(92.7%) | 12(66.7%) | 78(97.5%) | 90(91.8%) |
| 5-Year OS (%) | 29(65.9%) | 141(95.9%) | 170(89.0%) | 12(66.7%) | 76(95.0%) | 88(89.8%) |

*Data in parentheses are interquartile ranges.

Discussion

In the present study, nomograms merging pathological parameters were built to predict the 1-, 3-, and 5-year OS rates of patients with ECA. Both identification and calibration were confirmed, and the nomograms will have a wide range of applications. According to the ROC curve and detrended correspondence analysis, the prognostic nomogram exhibited greater accuracy in patients with ECA than the current FIGO staging system. Furthermore, it could classify patients with ECA into low- and high-risk subpopulations, implying that it could routinely be applied to prognose ECA.

Previous research has demonstrated that histological type, DOI, stromal invasion, LVI, and LNM are highly prognostic factors, and that they currently influence patient management[17–19]. Comparing HPVA and NHPVA reveals essential differences in tumor behavior and patient survival, with significantly worse clinical outcomes in patients with NHPVA[20]. Tumors with a DOI of less than 3 mm (FIGO stage IA1) have lower rates of lymph-node metastases, parametrial spread, and recurrence than larger tumors (stage IA2, IB1, and IB2). Measurement of DOI is restricted[21]. Thus, stromal invasion status can complement, but should not replace, the DOI metric. Depending on variables such LVI, prognosis regarding fertility may be approved[22, 23].

Our nomogram scoring systems seemed to have outstanding capacities for prognosing ECA. Previous studies attempted to predict outcome in cervical cancer. For example, one study analyzed a four-factor model (histology, tumor size, deep stromal invasion, and LVI). The authors found that the presence of any two factors may predict recurrence in patients with cervical cancer[24]. Previous studies showed that DOI, LVI, LNM, and invasion patterns were strong independent predictors of disease-specific survival in...
ECA[19, 25–27]. By incorporating a log of odds between the number of positive lymph nodes and the number of negative lymph nodes, the nomogram by Wang may be superior to the FIGO staging system in predicting OS in cervical cancer[28]. The present study enlarged the analysis of individual H&E morphological characteristics into a nomogram model for estimating survival, proving the histological signature's incremental signature for individualized OS estimation. Our model consisted of five histological characteristics and provided a non-invasive, quick, low-cost, and reproducible method for collecting phenotypic information. As such, it may inform attempts to improve personalized medicine.

However, the present study had several deficiencies. Firstly, there may have been a selection bias because patients with ECA in situ were not enrolled in the nomograms. Secondly, our study only assessed OS prognosis in patients with ECA. Thirdly, the sample size was rather small. Therefore, another study must be conducted to verify the nomogram.

Conclusions

In summary, we generated new nomograms to prognose the OS rate in patients with ECA. Our simple and explicit nomograms have good clinical application value, and they show good discrimination and calibration ability. They may be a useful tool for assessing prognosis and managing treatment in patients with ECA.

Declarations

Ethics approval and consent to participate

This study was approved by the Clinical Research Ethics Committee of the Sun Yat-sen University Cancer Center, and all patients provided written informed consent at the first visit to our center.

Consent for publication

Not applicable.

Availability of data and materials

The authenticity of this article has been validated by uploading the key raw data onto the Research Data Deposit public platform (www.researchdata.org.cn) with the approval RDD number RDDB2020000652.

Competing interests

The authors declare that they have no competing interests.

Funding

This work was supported by the National Natural Science Foundation of China (No. 8207100308).
Authors’ contributions

Conception and design: Rong-Zhen Luo. Performing experiments: Li-Li Liu and Xia Yang. Drafting of the article: Li-Li Liu and Shu-Lin Chen. Acquisition and interpretation of data, review, editing and approval of the manuscript: all authors.

Acknowledgements

We thank Sun Yat-sen University Cancer Center for providing support on research conditions in this study.

References

1. Smith HO, Tiffany MF, Qualls CR, Key CR: The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States—a 24-year population-based study. Gynecol Oncol 2000, 78(2):97-105.

2. Kenny SL, McBride HA, Jamison J, McCluggage WG: Mesonephric adenocarcinomas of the uterine cervix and corpus: HPV-negative neoplasms that are commonly PAX8, CA125, and HMGA2 positive and that may be immunoreactive with TTF1 and hepatocyte nuclear factor 1-beta. Am J Surg Pathol 2012, 36(6):799-807.

3. Ito M, Minamiguchi S, Mikami Y, Ueda Y, Sekiyama K, Yamamoto T, Takakura K: Peutz-Jeghers syndrome-associated atypical mucinous proliferation of the uterine cervix: a case of minimal deviation adenocarcinoma (‘adenoma malignum’) in situ. Pathol Res Pract 2012, 208(10):623-627.

4. Kocken M, Baalbergen A, Snijders PJ, Bulten J, Quint WG, Smedts F, Meijer CJ, Helmerhorst TJ: High-risk human papillomavirus seems not involved in DES-related and of limited importance in nonDES related clear-cell carcinoma of the cervix. Gynecol Oncol 2011, 122(2):297-302.

5. Karamurzin YS, Kiyokawa T, Parkash V, Jotwani AR, Patel P, Pike MC, Soslow RA, Park KJ: Gastric-type Endocervical Adenocarcinoma: An Aggressive Tumor With Unusual Metastatic Patterns and Poor Prognosis. Am J Surg Pathol 2015, 39(11):1449-1457.

6. Kojima A, Mikami Y, Sudo T, Yamaguchi S, Kusanagi Y, Ito M, Nishimura R: Gastric morphology and immunophenotype predict poor outcome in mucinous adenocarcinoma of the uterine cervix. Am J Surg Pathol 2007, 31(5):664-672.

7. RJ K, ML C, CS H, RH Y: WHO Classification of Tumors of Female Reproductive Organs, 4th ed. Lyon: IARC, WHO Press 2014.

8. Ronnett BM: Endocervical adenocarcinoma: selected diagnostic challenges. Mod Pathol 2016, 29 Suppl 1:S12-28.

9. Baalbergen A, Ewing-Graham PC, Hop WC, Struijk P, Helmerhorst TJ: Prognostic factors in adenocarcinoma of the uterine cervix. Gynecol Oncol 2004, 92(1):262-267.

10. Stolnicu S, Barsan I, Hoang L, Patel P, Terinte C, Pesci A, Aviel-Ronen S, Kiyokawa T, Alvarado-Cabrero I, Pike MC et al. International Endocervical Adenocarcinoma Criteria and Classification (IECC): A New
Pathogenetic Classification for Invasive Adenocarcinomas of the Endocervix. Am J Surg Pathol 2018, 42(2):214-226.

11. Diaz De Vivar A, Roma AA, Park KJ, Alvarado-Cabrero I, Rasty G, Chanona-Vilchis JG, Mikami Y, Hong SR, Arville B, Teramoto N et al: Invasive endocervical adenocarcinoma: proposal for a new pattern-based classification system with significant clinical implications: a multi-institutional study. Int J Gynecol Pathol 2013, 32(6):592-601.

12. Roma AA: Patterns of Invasion of Cervical Adenocarcinoma as Predicators of Outcome. Adv Anat Pathol 2015, 22(6):345-354.

13. Roma AA, Mistretta TA, Diaz De Vivar A, Park KJ, Alvarado-Cabrero I, Rasty G, Chanona-Vilchis JG, Mikami Y, Hong SR, Teramoto N et al: New pattern-based personalized risk stratification system for endocervical adenocarcinoma with important clinical implications and surgical outcome. Gynecol Oncol 2016, 141(1):36-42.

14. Roma AA, Fadare O: The pattern is the issue: recent advances in adenocarcinoma of the uterine cervix. Virchows Arch 2018, 472(6):897-905.

15. Rivera-Colon G, Chen H, Niu S, Lucas E, Holloway S, Carrick K, Gwin K, Lea J, Zheng W: Cervical Adenocarcinoma: Histopathologic Features From Biopsies to Predict Tumor Behavior. Am J Surg Pathol 2020, 44(2):247-254.

16. Ito K, Seguchi K, Shimazaki H, Takahashi E, Tasaki S, Kuroda K, Sato A, Asakuma J, Horiguchi A, Asano T: Tumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma. Oncol Lett 2015, 9(1):125-130.

17. Parra-Herran C, Taljaard M, Djordjevic B, Reyes MC, Schwartz L, Schoolmeester JK, Lastra RR, Quick CM, Laury A, Rasty G et al: Pattern-based classification of invasive endocervical adenocarcinoma, depth of invasion measurement and distinction from adenocarcinoma in situ: interobserver variation among gynecologic pathologists. Mod Pathol 2016, 29(8):879-892.

18. Stolnicu S, Hoang L, Chiu D, Hanko-Bauer O, Terinte C, Pesci A, Aviel-Ronen S, Kiyokawa T, Alvarado-Cabrero I, Oliva E et al: Previous study identified a four-factor model (histology, tumor size, deep stromal invasion and LVI) in which the presence of any two factors may be useful for predicting recurrence in patients with cervical cancer. Am J Surg Pathol 2019, 43(4):466-474.

19. Spaans VM, Scheunhage DA, Barzaghi B, de Kroon CD, Fleuren GJ, Bosse T, Jordanova ES: Independent validation of the prognostic significance of invasion patterns in endocervical adenocarcinoma: Pattern A predicts excellent survival. Gynecol Oncol 2018, 151(2):196-201.

20. Rodriguez-Carunchio L, Soveral I, Steenbergen RD, Torne A, Martinez S, Fuste P, Pahisa J, Marimon L, Ordi J, del Pino M: HPV-negative carcinoma of the uterine cervix: a distinct type of cervical cancer with poor prognosis. BJOG 2015, 122(1):119-127.

21. Poynor EA, Marshall D, Sonoda Y, Slomovitz BM, Barakat RR, Soslow RA: Clinicopathologic features of early adenocarcinoma of the cervix initially managed with cervical conization. Gynecol Oncol 2006, 103(3):960-965.
22. Hacker NF: **Revised FIGO staging for carcinoma of the vulva.** *Int J Gynaecol Obstet* 2009, **105**(2):105-106.

23. Roma AA, Park KJ, Xie H, De Vivar AD, Alvarado-Cabrero I, Rutgers JKL, Barbuto D, Silva EG: **Role of Lymphovascular Invasion in Pattern C Invasive Endocervical Adenocarcinoma.** *Am J Surg Pathol* 2017, **41**(9):1205-1211.

24. Ryu SY, Kim MH, Nam BH, Lee TS, Song ES, Park CY, Kim JW, Kim YB, Ryu HS, Park SY et al: **Intermediate-risk grouping of cervical cancer patients treated with radical hysterectomy: a Korean Gynecologic Oncology Group study.** *Br J Cancer* 2014, **110**(2):278-285.

25. Byun JM, Cho HJ, Park HY, Kim YN, Lee KB, Sung MS, Jeong CH, Jeong DH: **Clinical significance of the pattern-based classification in endocervical adenocarcinoma, usual and variants.** *Int J Clin Oncol* 2019, **24**(10):1264-1272.

26. Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ: **A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study.** *Gynecol Oncol* 1999, **73**(2):177-183.

27. McCluggage WG: **New developments in endocervical glandular lesions.** *Histopathology* 2013, **62**(1):138-160.

28. Wang C, Yang C, Wang W, Xia B, Li K, Sun F, Hou Y: **A Prognostic Nomogram for Cervical Cancer after Surgery from SEER Database.** *J Cancer* 2018, **9**(21):3923-3928.

**Supplementary Information**

| Models                      | Correlation coefficients a | P value |
|-----------------------------|----------------------------|---------|
| **For training cohort**     |                            |         |
| Our model vs. Figo stage    | 0.473                      | < 0.001 |
| Our model vs. Treatment     | 0.512                      | < 0.001 |
| **For validation cohort**   |                            |         |
| Our model vs. Figo stage    | 0.311                      | 0.002   |
| Our model vs. Treatment     | 0.575                      | < 0.001 |

a: Pearson's correlation coefficient.

**Supplementary Figure-1.** Representative images for other histopathological features in paraffin embedded ECA samples. Representative images for growth pattern A, B, C (A), nuclear grade (B), tumor...
cell necrotic debris (C), tumor giant cells (D), tumoral TILs (E) and stromal TILs (F) were shown.

**Supplementary Figure-2.** The best cut-off values for subgroups were determined by X-tile in all ECA cases. The best cut-off values for low-risk group and high-risk group were determined by X-tile.

**Supplementary Figure-3.** Bioinformatic analyses indicated that the subgroups based on the 5 histologic features, FIGO stage and treatment. (A-B) Heatmaps showing the results of 3 subgroups based on the 5 predictors from our nomogram model, FIGO stage and treatment for training cohort and validation cohort. (C-D) The circus diagram showed that our model, FIGO stage and treatment were significantly correlated in training cohort and validation cohort.